Objective To determine the extent of financial toxicity (FT) among cancer survivors, identify the determinants and how FT is measured. Methods A systematic review was performed in MED-LINE, CINAHL and PsycINFO, using relevant terminology and included articles published from 1 January, 2013 to 30 June, 2016. We included observational studies where the primary outcomes included FT and study samples were greater than 200. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Results From 417 citations, a total of 25 studies were included in this review. Seventy outcomes of FT were reported with 47 covering monetary, objective and subjective indicators of FT. A total of 28-48% of patients reported FT using monetary measures and 16-73% using subjective measures. The most commonly reported factors associated with FT were: being female, younger age, low income at baseline, adjuvant therapies and more recent diagnosis. Relative to non-cancer comparison groups, cancer survivors experienced significantly higher FT. Most studies were cross-sectional and causal inferences between FT and determinants were not possible. Measures of FT were varied and most were not validated, while monetary values of out-of-pocket expenses included different cost components across studies. Conclusions A substantial proportion of cancer survivors experience financial hardship irrespective of how it is measured. Using standardised outcomes and longitudinal designs to measure FT would improve determination of the extent of FT. Further research is recommended on reduced work participation and income losses occurring concurrently with FT and on the impacts on treatment nonadherence.
Introduction
'The greater threats to our national public health system lie in the increasing role of consumer copayments and the power of vested interests that stifle policy innovation in health' (Stephen Duckett in response to privatisation of Australian Medicare, Director, Health Program, Grattan Institute, 23 June, 2016).
Patients with cancer can face serious financial challenges. In part, this is owing to the high costs associated with advancements in technologies and treatments such as new pharmacotherapies, surgical techniques, imaging and genetic testing [1] . Cancer survivors are also living longer with their cancer as a chronic illness and with the accompanying demands to monitor the disease and its sequelae [2] . As most health systems, including both public and private providers, face tight budgets, there is increasing reliance on patients to make larger co-payments and financial contributions to their healthcare. Even in countries where there is universal healthcare or when individuals have health insurance, additional patient out-of-pocket (OOP) expenses are commonplace [1, 3] .
The term 'financial toxicity' (FT) is defined in oncology research and practice to describe the financial distress or hardship that may be a side effect of cancer treatment [1, 4, 5] . Aptly coined for the financial pain of receiving cancer treatment, the term describes persons with high OOP medical expenses and the impacts on poorer quality of life and reduced healthcare. In this sense, it is very similar to other treatment toxicities such as neutropenia, nausea, vomiting, insomnia or depression that lead to poorer patient outcomes and at times treatment delays/discontinuation. There are several options faced by patients when they are unable to afford medical care [1, 4, 5] : (1) they borrow money; (2) they forgo other types of spending to pay for the healthcare; (3) they reduce their use of care (i.e., forgo or delay appointments, do not fill scripts, ration medications) or, in severe cases; (3) they forgo treatment entirely (including not presenting to a physician to diagnose cancer).
There is no gold-standard definition of FT and the terms financial hardship, financial burden and FT are used interchangeably. However, the degree of financial burden has two contributors: high medical payments by individuals and reduced income while being treated or recovering from cancer. The combination of both a household's financial outgoings and incomings determines the extent of financial burden. The ways that individuals cope with financial burden fall into two broad categories: raising income (i.e., seeking financial assistance, early return to work, increasing debt/borrowings) or reducing spending (i.e., forgoing or delaying healthcare, choosing a less expensive option).
The experience of financial hardship varies for citizens in different regions around the world. In low-income countries, patients with cancer may not even present to health services for care when symptoms arise or only present to a doctor when the cancer has spread and death is imminent [6] . Exacerbating this problem is the poor provision of a public health sector for citizens or other cultural or geographical barriers to receive cancer treatment [7] . In high-income countries, patients with cancer often believe they are sufficiently protected from high medical costs through their health insurance policies only to discover inadequate coverage and subsequent 'bill shock' when invoices arrive [5] . Health systems classified as having 'universal health coverage' may not be comprehensive in practice, for example, Australia does not have universal dental services [3] .
Although any disease may cause financial hardship among households, the term 'financial toxicity' originated in the context of cancer [5] . This is because of the very high cost of oncology medicines, the multiple and protracted treatment regimens, prolonged survival in cancer patients and ageing populations with a subsequent increased prevalence of common cancers [5] . The purpose of this review was to address the following research questions: What is the extent of FT among cancer survivors? How is it measured? What are the factors associated with FT? We intentionally kept this review focused on studies published since January 2013 to provide the most up-to-date evidence on this topic. This enabled the review to be manageable, reflect current data collections and exclude exploratory studies. We also aimed to identify the latest measurement approaches on this topic, those that may have been derived from the exploratory studies.
Methods

Search Strategy
The review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for systematic reviews [8] . We reviewed the recent medical literature on FT of cancer care using MED-LINE, PsycINFO and CINAHL. Reference lists of the included articles were screened to identify any other eligible studies. We included all types of cancer and all ages of cancer survivors. Studies that examined FT as a result of treatment (broadly including cost, expense, treatment cost, OOP expenses, economic burden, financial toxicity, financial hardship, financial burden, financial effect, financial stress, co-payment) in cancer patients were the primary focus. To increase homogeneity and comparability of included studies, papers assessing productivity losses or return to work issues but did not consider FT were excluded. We excluded studies that did not have solely cancer samples and the following study designs: qualitative studies, literature reviews, cost-effectiveness studies, commentaries and published abstracts. Qualitative studies were excluded because they tend to address why and how participants might be experiencing FT, while cost-effectiveness studies primarily deal with evaluating comparative cancer interventions and therefore FT is not their primary focus.
The following inclusion were applied: FT of cancer patients as a result of treatment is the primary interest; published between January 2013 and June 2016; any type of cancer; and a quantitative study. The following exclusion criteria were applied: FT was not the main focus of the article; published prior to 2013; funded by industry; wrong study design (as defined above); and small sample size (n\ 200).
Search Terms
We grouped our review topic into four groups: (1) cancer, (2) patients, (3) cost, and (4) health outcomes. Synonyms and related terms were detailed (as below). For each of the terms in the four groups, we used Boolean operator 'OR' and between the groups we used 'AND'. We used medical subject headings (MeSH) when available. Searches were restricted by date but not limited by language. To increase the accuracy of results and to minimise screening of irrelevant studies, only searches with \50 results were exported and duplicates removed. The search strategy was developed by one researcher and validated by a second researcher. Final searches were performed on 22 July, 2016.
Screening and Data Extraction
Initially, titles were screened for inclusion according to our pre-specified inclusion criteria. Subsequently, abstracts of potentially eligible citations were screened. Reasons for exclusion were documented. This process was independently performed by two authors (KM and LG) and discrepancies were discussed until an agreement was reached.
The assessment of the full-text articles retrieved was examined for inclusion by two reviewers who shared this task equally and together agreed on the final set of included studies. Key information of eligible articles was extracted into a table by two authors (KM and LG) to summarise the features and main findings of the studies.
Data Synthesis and Quality
Study quality was assessed using the National Institute of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [9] . This tool asks 14 questions about issues relating to the risk of bias in the studies but it is not designed to be scored. Rather, the questions prompt the reviewer to assess study limitations. We did not synthesise outcomes in a meta-analysis due to heterogeneous outcomes, cancer types and time frames; instead, a narrative synthesis was undertaken.
Results
Literature Search
Our initial database search revealed 384 citations of which 74 were duplicates. Reference screening of these papers revealed a further 33 potentially eligible studies. After screening 343 titles, 232 were excluded as shown in Fig. 1 . Abstract screening of 111 citations resulted in 31 full-text articles assessed for eligibility. After further excluding six records, the final number of studies included in the review was 25 ( Table 1 ). The main reasons for exclusion were because of an irrelevant topic, FT not being the primary outcome, focus on non-patient costs, small sample size (n \ 200) and wrong study type.
Description of Studies
The included studies were conducted in a range of countries but predominantly from USA: USA (14) [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , Singapore (1) [24] , Korea (1) [25] , Ireland (2) [26, 27] , Italy (1) [28] , India (1) [7] , Canada (2) [29, 30] , Australia (1) [31] and Association of Southeast Asian Nations (2) [6, 32] (Table 1 ). The 25 studies covered 271,732 cancer survivors, with study samples ranging from 268 to 197,840. Half the studies (14) included participants with any type of cancer [6, 7, 10, 12, 15, 16, 20-25, 28, 32] , one for adultonset cancers [17] , four had a mix of two to three cancers (including breast and prostate cancers) [11, 19, 26, 27] , two had breast cancer [14, 30] , two had prostate cancer [29, 31] , and two had blood cancers [13, 18] . Eighteen studies (72%) were cross-sectional and the remainder were prospective or retrospective cohort studies. The timing of the participants since their cancer diagnosis varied significantly across the studies but can be divided into those who collected data relatively early after diagnosis (within 2 years), longer term (beyond 2 years) and studies with participants 'any time' since diagnosis. Table 2 presents the outcomes of the quality assessment. The main strengths of the studies were that all had clearly stated objectives, had reasonable sample sizes (mean of 3079 excluding the extremely high sample in Ramsey 2013), many had response rates over 50%, had clear population inclusion criteria, clearly stated outcome and independent variables, and mostly used multivariable analyses to address confounding. The main limitations were that few studies were population based, most were cross-sectional and diverse outcome measures hampered across-study comparisons. With cross-sectional designs, causal inferences between FT and determinants were not possible. It is probable that financial hardship existed prior to the cancer or as a result of other co-morbidities and the cancer experience might have not caused but exacerbated FT. Directionality and temporality issues are also present in these cross-sectional designs. Studies using administrative data sets did not consider sample size calculations and therefore could be considered exploratory analyses. Although some samples were selected from large population-based datasets where response rates were not applicable, others could not be determined [6, 7, 15, 16, 19, 31] . Those conducting surveys or interviews mostly had participation rates over 50% (12 studies) and a few did not [22] [23] [24] 28] . The generalisability of the study samples is therefore questionable. The choice of 'financial burden' outcome was often clearly defined, but remained subjective, unvalidated or tested for reliability. Conversely, the monetary assessments of OOP costs included different cost components, covered different time periods and were still open to recall bias. In addition, the reference of OOP costs to income levels was not made in which to judge burden of health relative to other household expenditures. This is important because, paradoxically, high OOP costs paid by patients are only possible with sufficient income and 
Quality of Studies
Summary of Findings
The measures of FT varied widely among the studies. They were categorised as:
1. monetary measures: currency values of OOP costs and percentage of OOP costs to income ratios; 2. objective measures: question sets on tangible solutions to ease financial burden such as to increase debt levels, borrow money from family or friends, sell assets, withdraw money from retirement or savings funds, file for bankruptcy; and 3. subjective measures: question sets on perceptions of cancer-related financial burden and psychological impact.
Within the monetary measures of OOP costs, these included either direct medical expenses or direct and indirect expenses (i.e. travel, accommodation, parking).
The studies reported 47 measures of FT with most reporting more than one measure using the above categories; 22 (47%) monetary measures, 9 (21%) objective measures and 16 (34%) subjective measures. In addition to quantifying FT, the impacts or consequences of FT were also outcomes for some studies (16 total measures). These included treatment non-adherence, changes made to insurances, choice of end-of-life care and health-related quality of life. Furthermore, changes to work participation occurring concurrently with FT were further reported by seven (10%) studies in the context of FT. Figure 2 specifically outlines the dimensions of financial burden including all the above measures (70 total outcomes). Direct comparisons across studies was problematic because of different outcome measures, different time periods covered and the statistical approaches used ranging from descriptive statistics or simple ratios to multivariate modelling.
When a definition of FT in monetary terms was provided, these varied from 'catastrophic spending' defined as OOP costs greater than 30% of household income [6, 32] , greater than 20% of household income [11] and the top quartile of OOP costs [30] . Nevertheless, the studies indicated the frequency of FT among cancer survivors ranged from 28 to 48% [6, 7, 11, 13, 22, 25] . When FT involved answering objective or subjective questions, the frequency of FT ranged from 16 to 73% [10, 16-19, 23, 24, 26] .
Most studies used statistical approaches to control for potential confounding in assessing FT as an outcome variable. Irrespective of the quantitative or subjective FT outcome used, in adjusted statistical models, the determinants of FT included: being female [6, 22] , low income at baseline [6, 22, 32] , loss of income [22, 30] , younger age [17, 18, 20, 22, 29] , adjuvant therapies [11, 17, 29, 30] , anti-neoplastic therapies [11, 15] more recent diagnosis [22, 29, 31] , advanced cancer [32] , no health insurance [6, 32] and living further away from treatment centres [28, 30] . Several studies excluded stage of cancer in their analyses [7, 17, 22] . Additionally, some ethnic groups in USA (African American [19] , Hispanics) consistently reported higher financial burden among cancer survivors, even after adjustment for income, education and employment [14, 17, 19, 22, 23] . Similarly, individuals with low income in developing countries with no universal health system or low levels of health insurance coverage, reported worse FT, in addition to poor survival rates [6, 32] . These authors point to the competing outcome of mortality when assessing FT in developing countries, which is not addressed in studies from developed countries. Baseline levels of FT [32] or financial stress [26] was also associated with FT following cancer treatment in two studies.
To examine FT specifically relating to cancer and no other competing co-morbidities, three studies assessed the extent of financial burden in cancer patients vs. non-cancer control groups [7, 11, 20] . All indicated a significantly higher burden for individuals with cancer relative to noncancer control groups. Cumulative 2-year spending on healthcare among a mixed cancer cohort in USA (1868 patients with cancer and 10,047 without cancer) was observed and 28% of patients with cancer reported a high OOP burden compared with 16% without cancer (p \ 0.001) [11] . Using propensity matching, a study in India by Mahal et al. found OOP costs were significantly higher (INR5311 vs. INR1079) annually per person in households of cancer survivors and translating to 36-44% of annual household expenditure on cancer-related care [7] . Ramsey et al. reported that patients with cancer were 2.65 times more likely to go bankrupt than age-matched people without cancer [20] .
Quality-of-life impacts were markedly worse for patients experiencing FT in three studies [16, 18, 27] with mental well-being especially affected [16, 18, 27] . FT was reported to be the strongest predictor of quality of life in the US study by Fenn et al. [12] . Compared with individuals not reporting FT, impacts of FT included treatment non-adherence (frequency 27% [10] , 32% [6] , 35-70% [15] ) higher delays in care (17 vs. 7.4%) [17] , more patients forgoing care [17] and lost insurance (29%) [13] . One study looking at the choice of end-of-life care [23] and found hospitalised intensive care was more common in those experiencing FT because this shifted costs to thirdparty payers even though dying at home was preferred by Reduced work participation and accompanying income loss was reported as being associated with FT in several studies [13, 22, 30] with a Canadian study reporting wage loss was the most important determinant of decline [30] .
Discussion
This review affirms FT to be a major issue affecting a large proportion of cancer survivors. Up to 48% of participants in the reviewed studies reported FT in monetary terms and this was even higher when measured in subjective terms. There were a range of possible questions or cost calculations that were used to constitute FT and this review has catalogued these as either monetary, objective (or tangible consequences) or subjective measures. The most commonly reported factors linked to FT were: being female, younger age, having a low income at baseline, receiving adjuvant therapies and having a recent diagnosis. High financial burden for cancer patients is in excess of that for persons not experiencing cancer (but possibly experiencing other chronic disease). The impact on patients can be debilitating to households, to quality of life and to optimal cancer care. Our findings are similar to an earlier review of ten studies, all cross-sectional but focussing on subjective measures of FT [33] . Although FT is a complex problem, greater awareness and acknowledgement of FT is likely to lead to solutions towards optimal patient outcomes by cancer care professionals, governments, patients and families, and welfare providers. FT is a household phenomenon and although this literature predominantly focusses on the financial outgoing expenses, it is also a function of the financial incomings, usually from employment, that are often reduced while undergoing cancer care. This is not Fig. 2 apparent in the studies in this review but as the authors of one study stated, wage losses from the cancer treatment and recovery may be more important than OOP costs incurred by households [30] . A critical underlying complication of the affordability of medical care is the potential for job loss, work absence and workplace discrimination experienced during the course of prolonged cancer treatment. This is most apparent in developing countries where those on low incomes experienced higher mortality rates (from lack of healthcare) and higher catastrophic spending levels [6, 32] .
Suggestions to ameliorate the financial burden for patients in tangible ways have included mandating the full disclosure by doctors of estimated fees and charges related to treatment from all sources, improved communication between health professionals and patients to raise any financial concerns and the ability of patients to return to work should they need/wish to, and creating opportunities for patients to make treatment decisions fully informed of the likely burden. Appropriate discussions about financial concerns should begin from the start of treatment and at critical time points (e.g. completion of treatment), preparing patients and their families for the potential financial effects that could have an ongoing impact. Furthermore, screening tools may assist health professionals to identify those patients at high risk and refer them to support services.
A limitation of the review was the complexity of the topic and the absence of firm definitions or a conceptual model informing this body of evidence. Beyond the scope of this review, we omitted the rich data covered by qualitative studies on this topic. However, the categories used in reporting the collective outcomes of the included studies may help researchers design studies in the future. It is encouraged that researchers use a standardised tool for assessing FT within cancer populations and there is one now available, which was published in 2014 [34] . Briefly, the COST-FACIT was developed by Souza et al., and is an 11-item survey covering objective and subjective questions covering financial stress and work-related issues during the previous 7 days and using a Likert scale from 'Not at all' to 'Very much' [34] . In addition, as work income reductions are an important aspect of FT, the Institute for Medical Technology Assessment Productivity Cost Questionnaire may also be useful in future research [35] . The Institute for Medical Technology Assessment Productivity Cost Questionnaire measures productivity losses of paid work as a result of absenteeism and presenteeism and unpaid work with 18 items and phrased over the previous 4 weeks [35] . Both these instruments are generic and are not confined to cancer populations and both developers have called for further validation studies [34, 35] . It is advisable to use both these tools to cover the employment and OOP aspects and to minimise the use of unvalidated tools.
In addition to being a direct patient concern, FT exposes serious system-level deficiencies around the way health systems are organised. Health system reforms in many settings are critical for minimizing FT and promoting equity in healthcare. Despite the developments for improving cancer control, the very high costs associated with cancer treatments is raising the issue of the capacity to afford these resources and whether budgets can sustain such spending. The Sustainable Development Solutions Network promotes universal healthcare and emphasizes that for nations to provide equality of access to necessary healthcare to their entire population, financing options that reduce OOP spending are fundamental [3] . Re-allocation of health resources can occur through, for example, investing in costeffective preventive care, reducing use of services that offer little or no benefit, linking payments to the value of services received and increasing the use of information technology to populations in hard-to-reach locations [3] . Omitted from these options are suggestions to increase user fees and/or private health insurance coverage, which serve only to exacerbate the difficulty for individuals meeting the financial demands of treatments. Health system structures and funding have a large influence on the experience of FT. At the extreme, this is emphasized in countries with poor or no public health system, where households pay entirely to receive treatment and clearly face catastrophic burdens, and high mortality [6] . However, the more granular differences among patients experiencing FT within complex health systems and shared funding models remain unknown. For patients with private health insurance, the review found mixed results as to whether FT was more or less protected. In Australia, men with prostate cancer experienced FT and higher OOP expenses when they were privately insured vs. public hospital patients [31] , which appears to be a product of the unregulated market in which specialists practice price discrimination [36] . However, the opposite was true in USA and other South East Asian countries, where patients without health insurance were more likely to report FT compared with those with health insurance [4, 6, 13, 22, 37] but, nevertheless were not always fully protected from FT.
In countries such as Australia, New Zealand, Canada and the UK, government funding of new healthcare services and interventions involve organisations that perform health technology assessments that assess the value of new medicines and other services (http://www.inahta.org/). Their role is to weigh up the expected costs of their wide adoption and their patient outcomes and safety. Often, the benefits of new cancer therapies for metastatic disease are small, and may not provide sufficient value at the prices private industry seek for their provision. While these assessments appear lengthy, they are critical in the balanced and careful adoption of safe, effective and cost-effective treatments [38] . Developing countries in south-east Asia and Latin America are also adopting these systematic value assessments because they offer a thorough and ethical basis for decision making involving public funds. From the patient's perspective, although new high-cost cancer medicines are often refused or delayed for public funding, leading to patient advocacy, crowd funding and medical tourism to access them, they may not understand the lack of evidence base supporting these medicines. There is an important role for public engagement in health technology assessment to enable their views to be incorporated into funding decisions [39] .
Further research is warranted on FT and its impacts on treatment non-adherence in the longer term. There are several other reasons aside from affordability explaining non-adherence ranging from patient medication beliefs, patient age, extent of side effects, multiple doses, and provider education and communication skills [40] . The studies in this review indicate short-term observations of non-adherence but there are likely to be potential health system costs that have not been thoroughly assessed. Nonadherence may be temporarily cost saving for patients but it has wider downstream implications for health services [41] . For new high-cost oral anti-neoplastic agents within oncology, we are only beginning to understand that high levels of non-adherence occur despite the more convenient oral mode of delivery [40] .
Conclusions
Minimising FT is critically important for patients and also important for health system structure and reforms. Patients and providers need to take control at seeking information on costs and exploring inexpensive options. More recognition of both the income and expenses side of financial hardship needs to occur among clinicians and researchers. Using standardised tools, prospective and longitudinal designs will improve our understanding of FT.
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